TET2 and TP53 Mutations Cooperatively Modulate the Response to Inflammation to Promote Leukemic Transformation
Pablo Sánchez Vela, Brianna Kelly, Claudia Brady, Jonathan Foox, Jacob Lowell Glass, Richard P. Koche, Matthew G. Wereski, Isabelle Sara Csete, Sebastian El Ghaity-Beckley, Bridget Kelly Marcellino, Ross L. Levine, Alan H. Shih
This study shows that TET2 and TP53 mutations work together to promote leukemic transformation by altering inflammatory responses and chemotherapy tolerance in hematopoietic stem cells.
bioRxiv · Jan 20, 2026 · PreprintCancer Biology